An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

被引：0
|
作者：
Gambacorti-Passerini, Carlo [1 ]
Kim, Dong-Wook [2 ]
Kantarjian, Hagop M. [3 ]
Brummendorf, Tim H. [4 ,5 ,11 ]
Dyagil, Irina [6 ]
Griskevicius, Laimonas [7 ]
Malhotra, Hemant [8 ]
Goh, Yeow-Tee [9 ]
Wang, Junyuan [10 ]
Gogat, Karin [10 ]
Cortes, Jorge [3 ]
机构：
[1] Univ Milano Bicocca, Monza, Italy
[2] Seoul St Marys Hosp, Seoul, South Korea
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[5] Univ Klinikum Aachen, Hamburg, Germany
[6] Ukraine Acad Med Sci, Res Ctr Radiat Med, Kiev, Ukraine
[7] Vilnius Univ Hosp, Santarigkio Klin, Vilnius, Lithuania
[8] SMS Med Coll & Hosp, Birla Canc Ctr, Jaipur, Rajasthan, India
[9] Singapore Gen Hosp, Singapore 0316, Singapore
[10] Pfizer Inc, Cambridge, MA USA
[11] Univ Klinikum Aachen, Aachen, Germany
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [41] The Incidence of Bcr-Abl Mutations and Their Impact on Clinical Outcome in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients Treated with Bosutinib Versus Imatinib in the BELA Trial
    Kim, Dong-Wook
    Cortes, Jorge E.
    Maslyak, Zvenyslava
    Wong, Raymond
    Duvillie, Ladan
    Powell, Christine
    Countouriotis, Athena
    Bruemmendorf, Tim H.
    BLOOD, 2011, 118 (21) : 1192 - 1192
  • [42] Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
    Lipton, Jeffrey H.
    Chuah, Charles
    Guerci-Bresler, Agnes
    Rosti, Gianantonio
    Simpson, David
    Assouline, Sarit
    Etienne, Gabriel
    Nicolini, Franck E.
    Le Coutre, Philipp
    Clark, Richard
    Stenke, Leif
    Andorsky, David
    Oehler, Vivian
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Haluska, Frank G.
    Baccarani, Michele
    Cortes, Jorge E.
    Guilhot, Francois
    Hochhaus, Andreas
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    Shah, Neil P.
    Talpaz, Moshe
    Deininger, Michael W.
    BLOOD, 2014, 124 (21)
  • [43] Upfront Combined Hydroxyurea and Imatinib versus Imatinib Monotherapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Randomized Controlled Trial
    Chetia, Rituparna
    Palepu, Sarika
    Dutta, Vikramjeet
    Bandyopadhyay, Arkapal
    Mathew, Anisha
    Vaniyath, Sudeep
    Bakliwal, Anamika
    Chattopadhyay, Debranjani
    Rajoreya, Ashok
    Dhamija, Puneet
    Naithani, Manisha
    Singh, Neha
    Nath, Uttam Kumar
    SOUTH ASIAN JOURNAL OF CANCER, 2024,
  • [44] EPIC: A phase III randomized, open-label study of ponatinib versus imatinib in adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Lipton, Jeffrey H.
    Deininger, Michael W. N.
    Lustgarten, Stephanie
    Turner, Christopher D.
    Rivera, Victor M.
    Clackson, Tim
    Baccarani, Michele
    Cortes, Jorge E.
    Guilhot, Francois
    Hochhaus, Andreas
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    Shah, Neil P.
    Taipaz, Moshe
    Haluska, Frank G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial
    Brummendorf, Tim H.
    Cortes, Jorge E.
    Milojkovic, Dragana
    Gambacorti-Passerini, Carlo
    Clark, Richard E.
    le Coutre, Philipp D.
    Garcia-Gutierrez, Valentin
    Chuah, Charles
    Kota, Vamsi
    Lipton, Jeffrey H.
    Rousselot, Philippe
    Mauro, Michael J.
    Hochhaus, Andreas
    Monroy, Rafael Hurtado
    Leip, Eric
    Purcell, Simon
    Yver, Anne
    Viqueira, Andrea
    Deininger, Michael W.
    BLOOD, 2020, 136
  • [46] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Abbott, Brian L.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 272 - 281
  • [47] Bosutinib Versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia: Final 5-year Results From the BFORE Trial
    Milojkovic, Dragana
    Brummendorf, Tim H.
    Cortes, Jorge E.
    Gambacorti-Passerini, Carlo
    Clark, Richard E.
    Le Coutre, Philipp
    Garcia-Gutierrez, Valentin
    Chuah, Charles
    Kota, Vamsi
    Lipton, Jeffrey H.
    Rousselot, Philippe H.
    Mauro, Michael J.
    Hochhaus, Andreas
    Monroy, Rafael Hurtado
    Leip, Eric
    Purcell, Simon
    Yver, Anne
    Viqueira, Andrea
    Deininger, Michael W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 23 - 25
  • [48] MICRORNAS EXPRESSION IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE
    Fallah, Parviz
    Zamanizadeh, Ayeh
    Obeidi, Narges
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 : 37 - 37
  • [49] Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
    Do, Young Rok
    Kwak, Jae-Yong
    Kim, Jeong A.
    Kim, Hyeoung Joon
    Chung, Joo Seop
    Shin, Ho-Jin
    Kim, Sung-Hyun
    Bunworasate, Udomsak
    Choi, Chul Won
    Zang, Dae Young
    Oh, Suk Joong
    Jootar, Saengsuree
    Reksodiputro, Ary Harryanto
    Lee, Won Sik
    Mun, Yeung-Chul
    Kong, Jee Hyun
    Caguioa, Priscilla B.
    Kim, Hawk
    Park, Jinny
    Kim, Dong-Wook
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (02) : 303 - 312
  • [50] Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study
    Takaaki Ono
    Masayuki Hino
    Itaru Matsumura
    Shin Fujisawa
    Kenichi Ishizawa
    Emiko Sakaida
    Naohiro Sekiguchi
    Chiho Ono
    Mana Aizawa
    Yusuke Tanetsugu
    Yuichiro Koide
    Naoto Takahashi
    International Journal of Hematology, 2022, 116 : 871 - 882
12345